Comparison of Nodal Staging in Endometrial Cancer

Inclusion Criteria:

• Surgical candidate for complete hysterectomy and bilateral salpingooophorectomy withpelvic and aortic lymphadenectomy
• Histologically or cytologically confirmed endometrioid-type endometrial cancerconfined to the uterine corpus
• No clinical evidence of extra-uterine disease on pre-operative evaluation.
• Prior systemic chemotherapy is allowed so long as it was at least five years prior tostudy enrollment, and there is no evidence of disease after such therapy.
• Age ≥18 years.
• Life expectancy (estimated survival) of at least 6 months.
• AST(SGOT)/ALT(SGPT) < 3.0X upper limit of normal
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• GOG/ECOG Performance Status greater than 2
• Non-endometrioid cell type
• Clinical evidence of disease that extends beyond the uterus, including the presence ofsuspicious aortic or inguinal nodes on imaging or clinical exam
• Previous vaginal, pelvic or abdominal irradiation
• Chemotherapy, hormone therapy or immunotherapy directed at the present disease
• Previous pelvic lymphadenectomy or retroperitoneal surgery
• Patients with a prior or concurrent malignancy whose natural history or treatment hasthe potential to interfere with the safety or efficacy assessment of theinvestigational regimen
• Known allergy to iodine or indigocyanine green (ICG) tracer, or allergic reactions tocompounds of similar chemical or biologic composition
• Patients with uncontrolled intercurrent illness
• Patients with psychiatric illness/social situations that would limit compliance withstudy requirements
• Pregnant or lactating women